WHY DIFFERENTIATE FH?
FH IS UNDERDIAGNOSED, UNDERTREATED AND LIFE-THREATENING
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH.
- If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population.
- However, with optimal treatment an affected individual’s lifetime risk of cardiovascular disease approaches the risk in the general population.
FH IS ONE OF THE MOST COMMON GENETIC METABOLIC DISORDERS
FH has the prevalence of 1 in 200 to 1 in 250 individuals worldwide
FH is an autosomal dominant genetic condition caused by mutations in the low-density lipoprotein receptor (LDLR) gene, and less commonly, by mutations in the apolipoprotein B (apoB) or the proprotein convertase subtilisin/kexin (PCSK9) genes,all of which Inhibit LDL-C metabolism.
LDL-C is elevated from birth on and often leads to premature coronary heart disease resulting in early myocardial infarctions (MIs), in some cases as early as childhood in individuals with HoFH and second to sixth decade of life in individuals with HeFH. Individuals with FH have a significantly higher risk of developing CHD than unaffected individuals due to the lifetime exposure to elevated LDL-C.
The burden of LDL-C is significantly lower in individuals with early high-dose statin initiation
Recent data have confirmed earlier studies indication that FH accounts for roughly 13.000 MIs In the US per year. Initial insights from the FH Foundation’s CASCADE FH Registry™ suggest that over 25% of FH patients in the registry have heart disease by the time they are diagnosed and the age of diagnosis remains too late for most. In addition a majority of the patients in the registry require more than one medication to lower cholesterol.